CLN6 Antikörper (C-Term)

Produktnummer ABIN634889

Produktdetails anti-CLN6 Antikörper

Target: CLN6 (Ceroid-Lipofuscinosis, Neuronal 6, Late Infantile, Variant (CLN6))

Bindungsspezifität: C-Term

Reaktivität: Human, Maus, Ratte, Hund

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CLN6 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Spezifität: CLN6 antibody was raised against the C terminal of CLN6

Aufreinigung: Affinity purified

Immunogen: CLN6 antibody was raised using the C terminal of CLN6 corresponding to a region with amino acids RLFLDSNGLFLFSSFALTLLLVALWVAWLWNDPVLRKKYPGVIYVPEPWA

Anwendungsinformationen

Applikationshinweise: WB: 1 µg/mL
Optimal conditions should be determined by the investigator.

Kommentare:

CLN6 Blocking Peptide, catalog no. 33R-8022, is also available for use as a blocking control in assays to test for specificity of this CLN6 antibody

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Lyophilized powder. Add distilled water for a 1 mg/mL concentration of CLN6 antibody in PBS

Konzentration: Lot specific

Buffer: PBS

Handhabung: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.

Details zu CLN6

Target: CLN6 (Ceroid-Lipofuscinosis, Neuronal 6, Late Infantile, Variant (CLN6))

Andere Bezeichnung: CLN6 (CLN6 Produkte)

Synonyme: 1810065L06Rik antikoerper, AW743417 antikoerper, D9Bwg1455e antikoerper, nclf antikoerper, CLN4A antikoerper, HsT18960 antikoerper, cln6 antikoerper, zgc:103565 antikoerper, ceroid-lipofuscinosis, neuronal 6 antikoerper, CLN6, transmembrane ER protein antikoerper, CLN6, transmembrane ER protein S homeolog antikoerper, ceroid-lipofuscinosis, neuronal 6, late infantile, variant antikoerper, CLN6, transmembrane ER protein a antikoerper, Cln6 antikoerper, CLN6 antikoerper, cln6.S antikoerper, cln6a antikoerper

Hintergrund: CLN6 is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely CLN6 involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function.

Molekulargewicht: 36 kDa (MW of target protein)

Pathways: Glycosaminoglycan Metabolic Process